Prime Medicine, Inc. PRME
4.19 USD -0.08 (-1.87%)
Regular-session close
4.30 +0.11 +2.63%
Pre-market · Nov 17, 4:56 AM ET
4.10 Day range 4.36
2.67 52-week range 5.91
- YTD
- +20.75%
- 1 year
- +9.69%
Benzinga news
benzinga.com HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
benzinga.com Prime Medicine Q3 EPS $(0.22) Beats $(0.25) Estimate, Sales $4.213M Beat $1.206M Estimate Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.25) by 12 percent. This is a 31.25 percent increase over losses of $(0.32)…
benzinga.com Prime Medicine Commences $125M Offering Of Common Shares Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an…
